Loading stock data…
Krystal Biotech (KRYS)
$378.15+5.90 (+1.58%)
After Hours$382.00+3.85 (+1.02%)· Last close Jun 29
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Krystal Biotech, Inc. in the Healthcare sector is trading at $378.15 with a market capitalization of $9.6B. Wall Street consensus targets $349.78 (9 analysts), implying a -7.5% move over the next 12 months. The stock is currently near its 52-week high of $378.44, remaining 50.9% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply -7.5% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $116.36M↑ | $107.11M↑ | $97.80M↑ | $96.04M↑ | $88.18M |
| Gross Profit | $110.03M↑ | $100.51M↑ | $93.54M↑ | $88.88M↑ | $83.16M |
| Operating Income | $53.69M↑ | $44.27M↑ | $41.37M↑ | $39.31M↑ | $36.25M |
| Net Income | $55.93M↑ | $51.40M↓ | $79.36M↑ | $38.33M↑ | $35.73M |
Peer Comparison
JNJUNHPFE
Fundamentals
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremag...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.57B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
17.63%
Volume
Today's trading volume
286,956
Recent News
Krystal Biotech (KRYS) Soars 3.4%: Is Further Upside Left in the Stock?
Krystal Biotech (KRYS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Entertainment Stocks Madison Square Garden, Sphere Rally To New Highs
Entertainment leader Sphere stock continues to outperform in the current market environment, setting new highs.
The Brown Capital Management Small Company Fund Bets on Krystal Biotech (KRYS) for Its Resilient Revenue Stream
Brown Capital Management, an investment management company, released its first quarter 2026 investor letter for “The Brown Capital Management Small Company Fund”. A copy of the letter can be downloaded here. In the first quarter of 2026, the Small Company Fund (Investor shares) fell 19.78%, significantly lagging the Russell 2000 Growth index’s 2.81% decline. Worsened […]
3 Biotech Firms With Major Potential Catalysts in the Coming Months
The pharmaceutical industry is known for big risks and big rewards among investors; those willing to take on the risk may want to watch these firms.
These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead
They haven't peaked yet.